Roche Holding Ltd.
ROG
Real-time BATS EUROPE - 05/28 11:31:53 am
217.2CHF
0.00%
Prev.217.6000
Open218.9000
High218.9000
Low217.1500
Volume1 817 357
Financials
Sales 2018 55 741 M
EBIT 2018 18 660 M
R. net 2018 12 050 M
Debt 2018 4 564 M
Rend. 2018 3,98%
P/E ratio 2018 15,07
P/E ratio 2019 14,52
EV / Sales 2018 3,45x
EV / Sales 2019 3,25x
Capitalization 188 B
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The...
Sector :
Pharmaceuticals - NEC
Calendar :
2018-05-31 Presentation
Trading Rating :
Investor Rating :
Latest news
05/25AstraZeneca cancer drug hits second goal by extending survival
RE
05/21Roche Presents Positive Results From Hemlibra Trials
DJ
05/21GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III HAVEN 3 Study in Hemophilia A without Factor VIII Inhibitors
BU
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/16Reducing Use of Roche Drug for Breast Cancer Didn't Hurt Efficacy, Study Says
DJ
05/16ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel
BU
05/16ROCHE : Follow-up Phase III Data Showed Genentech’s Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live a Median of Almost Three Years Without Their Disease Worsening or Death
BU
05/15Roche's Actemra Gets FDA Nod for Pediatric Subcutaneous Use
DJ
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBearishBearish
Resistance230230234
Spread/Res.-5,4%-5,4%-6,9%
Spread/Supp.1,4%1,4%0,81%
Support214214216